加载页面时好像出了点问题.
我们的团队已经注意到了，但如果问题仍然存在，请使用电子邮件支持小工具联系我们。
| Trend | Peers | Company |
|---|---|---|
| Is return on equity increasing? | Yes | No |
| Is net profit margin increasing? | Yes | No |
| Is asset turnover increasing? | Yes | No |
| Is equity multiplier increasing? | Yes | Yes |
| Competitors Used |
|---|
| Cumberland Pharmaceuticals Inc. |
| RedHill Biopharma Ltd. |
| Corcept Therapeutics Incorporated |
| Ocular Therapeutix, Inc. |
| Elanco Animal Health Incorporated |
| Return on Equity Benchmarks | ||||||||
| Comparable Companies | ||||||||
| CPIX | RDHL | CORT | OCUL | ELAN | PHAT | |||
| Return On Equity | ||||||||
| Latest Twelve Months | -25% | -1709% | 24% | -95% | 5% | 205% | ||
| Fiscal Year - 1 | -19% | 363% | 21% | -128% | -18% | 273% | ||
| Fiscal Year - 2 | -14% | -860% | 23% | -115% | -1% | NA | ||
| Fiscal Year - 3 | -12% | -206% | 25% | -8% | -6% | NA | ||
| Fiscal Year - 4 | -13% | -76% | 24% | -430% | -8% | NA | ||
| Fiscal Year - 5 | -17% | -81% | 29% | -536% | 1% | NA | ||
| Average | -17% | -428% | 24% | -219% | -4% | 239% | ||
| Median | -16% | -143% | 24% | -121% | -4% | 239% | ||
| Benchmarks | Ticker | |||||||
| Cumberland Pharmaceuticals Inc. | NasdaqGS:CPIX | |||||||
| RedHill Biopharma Ltd. | NasdaqCM:RDHL | |||||||
| Corcept Therapeutics Incorporated | NasdaqCM:CORT | |||||||
| Ocular Therapeutix, Inc. | NasdaqGM:OCUL | |||||||
| Elanco Animal Health Incorporated | NYSE:ELAN | |||||||
| Financial Performance | ||||||||
| Comparable Companies | ||||||||
| (in millions) | CPIX | RDHL | CORT | OCUL | ELAN | PHAT | ||
| Latest Fiscal Year | Dec-24 | Dec-23 | Dec-24 | Dec-24 | Dec-24 | Dec-24 | ||
| LTM Period | Dec-24 | Jun-24 | Dec-24 | Dec-24 | Dec-24 | Dec-24 | ||
| Revenues | ||||||||
| Latest Twelve Months | 38 | 4 | 675 | 64 | 4,439 | 55 | ||
| Fiscal Year | 38 | 7 | 675 | 64 | 4,439 | 55 | ||
| Fiscal Year - 1 | 40 | 62 | 482 | 58 | 4,417 | 1 | ||
| Fiscal Year - 2 | 42 | 86 | 402 | 51 | 4,411 | NA | ||
| Fiscal Year - 3 | 36 | 64 | 366 | 44 | 4,764 | NA | ||
| Fiscal Year - 4 | 37 | 6 | 354 | 17 | 3,271 | NA | ||
| Fiscal Year - 5 | 34 | 8 | 306 | 4 | 3,071 | NA | ||
| Net Income | ||||||||
| Latest Twelve Months | (6) | (30) | 140 | (194) | 338 | (334) | ||
| Fiscal Year | (6) | 24 | 140 | (194) | 338 | (334) | ||
| Fiscal Year - 1 | (6) | (72) | 105 | (81) | (1,231) | (202) | ||
| Fiscal Year - 2 | (6) | (98) | 101 | (71) | (78) | (198) | ||
| Fiscal Year - 3 | (6) | (76) | 113 | (7) | (483) | (144) | ||
| Fiscal Year - 4 | (7) | (42) | 106 | (156) | (574) | (129) | ||
| Fiscal Year - 5 | (9) | (39) | 94 | (86) | 68 | (255) | ||
| Total Assets | ||||||||
| Latest Fiscal Quarter Prior | 82 | 35 | 622 | 252 | 14,362 | 414 | ||
| Latest Fiscal Quarter | 76 | 22 | 841 | 458 | 12,614 | 378 | ||
| Fiscal Year | 76 | 23 | 841 | 458 | 12,614 | 378 | ||
| Fiscal Year - 1 | 82 | 159 | 622 | 252 | 14,362 | 414 | ||
| Fiscal Year - 2 | 93 | 181 | 583 | 149 | 15,491 | 165 | ||
| Fiscal Year - 3 | 84 | 180 | 424 | 205 | 16,478 | 189 | ||
| Fiscal Year - 4 | 96 | 74 | 572 | 262 | 17,693 | 295 | ||
| Fiscal Year - 5 | 105 | 62 | 412 | 79 | 8,986 | 257 | ||
| Fiscal Year - 6 | 113 | 57 | 312 | 73 | 8,957 | 1 | ||
| Common Equity | ||||||||
| Latest Fiscal Quarter Prior | 30 | 3 | 507 | 91 | 6,223 | (73) | ||
| Latest Fiscal Quarter | 23 | 0 | 680 | 315 | 6,096 | (254) | ||
| Fiscal Year | 23 | 2 | 680 | 315 | 6,096 | (254) | ||
| Fiscal Year - 1 | 30 | (48) | 507 | 91 | 6,223 | (73) | ||
| Fiscal Year - 2 | 36 | 9 | 502 | 35 | 7,289 | (75) | ||
| Fiscal Year - 3 | 43 | 14 | 376 | 88 | 7,508 | 72 | ||
| Fiscal Year - 4 | 47 | 60 | 523 | 76 | 8,476 | 194 | ||
| Fiscal Year - 5 | 51 | 51 | 371 | (4) | 5,547 | 228 | ||
| Fiscal Year - 6 | 56 | 45 | 276 | 36 | 5,198 | (1) | ||